Russell Investments Group Ltd. cut its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 44.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,347 shares of the biotechnology company’s stock after selling 13,925 shares during the period. Russell Investments Group Ltd. owned about 0.09% of Enanta Pharmaceuticals worth $534,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of ENTA. WFG Advisors LP increased its stake in Enanta Pharmaceuticals by 3,243.2% in the fourth quarter. WFG Advisors LP now owns 1,471 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 1,427 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $204,000. Thrivent Financial for Lutherans purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $250,000. A.R.T. Advisors LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $268,000. Finally, Public Sector Pension Investment Board boosted its position in Enanta Pharmaceuticals by 10.0% in the fourth quarter. Public Sector Pension Investment Board now owns 9,900 shares of the biotechnology company’s stock valued at $332,000 after buying an additional 900 shares during the period. 67.33% of the stock is owned by hedge funds and other institutional investors.
Enanta Pharmaceuticals, Inc. (ENTA) traded up 2.88% during mid-day trading on Friday, reaching $37.47. 158,517 shares of the company were exchanged. Enanta Pharmaceuticals, Inc. has a one year low of $20.79 and a one year high of $38.40. The stock has a 50 day moving average of $34.53 and a 200-day moving average of $32.03. The stock’s market capitalization is $715.04 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.10. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The firm had revenue of $9 million for the quarter, compared to analyst estimates of $9.19 million. During the same quarter last year, the firm posted ($0.09) EPS. The business’s revenue was down 30.8% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: This piece was posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/07/24/enanta-pharmaceuticals-inc-nasdaqenta-shares-sold-by-russell-investments-group-ltd-updated-updated.html.
A number of research firms have weighed in on ENTA. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. JMP Securities upgraded shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research note on Tuesday, July 11th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $30.75.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.